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ercutaneous Coronary
ntervention Treatment
f Bifurcation Lesions—
Work in Progress
he Importance of Single-Center Studies*
aron V. Kaplan, MD, FACC
ebanon, New Hampshire
espite advances in interventional devices and techniques,
ifurcation lesions continue to present a formidable chal-
enge for the interventional cardiologist. Bifurcation lesions
re frequently encountered and are associated with increased
rocedural time, risk, restenosis, and thrombosis (1–3).
urthermore, as the interventional community begins to
ocus on left main revascularization, the importance of
reating bifurcation lesions will grow.
See page 185
The introduction of drug-eluting stents with its attendant
estenosis reduction has led many investigators to reexamine
tenting techniques for bifurcation lesions, many of which
ell from favor in the bare-metal era. This has included
e-examination of previously described techniques, such as,
stent, provisional T stent, culotte, and also has included
he development of new “drug-eluting stent era” techniques,
uch as crush (and its variations) and simultaneous kissing
tent/double barrel (4,5). The manuscript appearing in this
dition of JACC: Cardiovascular Interventions from Galassi
t al. (6), from Catania, Italy, presents their large, single
enter experience in the treatment of bifurcation lesions. As
n active clinician, as well as someone involved in the
evelopment of a dedicated bifurcation stent who is plan-
ing a large randomized trial (7), this paper is of particular
nterest.
Galassi et al. (6) report outcomes in 369 consecutive
atients with bifurcation lesions selected by the operator to
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Cardiology Section, Dartmouth Medical School and Cardiac Catheter-
zation Laboratories, Dartmouth-Hitchcock Medical Center, Lebanon, Newg
ampshire. Dr. Kaplan is a founder and director of Tryton Medical, Inc., a medical
evice start-up company developing a dedicated side branch stent.e treated with the “mini-crush” technique or a provisional
reatment strategy. Six-month angiographic follow-up was
btained in nearly 80% of patients. All lesions were treated
sing drug-eluting stents (sirolimus [Cypher/Cypher Select
tent] or paclitaxel [Taxus Liberte Stent]) according to the
trategy selected by the operator. The provisional strategy
as selected in nearly half (47%) of patients followed by
ini-crush in 37% of patients, with the remaining 16%
eceiving a mixture of other treatments (crush classic,
ulotte, and V stenting).
As would be anticipated, at baseline, patients in whom
ini-crush was selected had higher risk angiographic char-
cteristics, that is, Medina 1.1.1 and greater lesion length
in both main and side branch), than patients in whom a
rovisional strategy was selected. Both groups had similar
rocedural success rates. When the provisional strategy was
elected, the side branch was stented 34% of the time.
espite having angiographic markers associated with poorer
utcomes, patients treated with the mini-crush technique
rended toward improved clinical outcomes and had im-
roved angiographic outcomes with a 21% reduction in
umulative major adverse cardiac events (mini-crush: 20.6%,
rovisional: 26%, pNS). Binary angiographic side branch
estenosis was significantly reduced by 60% in the mini-
rush group (8.5%) when compared with restenosis rates in
atients treated with a provisional strategy (21.2%) (p 
.01). With the increased complexity and cost of the
ini-crush technique, one would expect that this technique
ould be reserved for higher risk patients
This investigation may be the largest series of its kind
uring the drug-eluting stent era and adds much to our
nderstanding of the treatment of this difficult lesion subset.
ather than viewing this study as another inning in the
ngoing rivalry between the provisional and mini-crush
eams with a winner and loser, it might be more constructive
o view these results as validating the ability of the operators
n Catania, Italy, to select the correct treatment strategy for
heir patients.
When examining these data, it is important to highlight
hat this is not a randomized study. However, although
andomized controlled trials remain a gold standard in
linical investigation, all too often data from single center
eries are inappropriately discounted. Large single center
eries such as the Catania series provide important infor-
ation and help calibrate results from randomized studies
valuating treatments for bifurcation lesions, for example,
ordic (8), BBC ONE (British Bifurcation Coronary
tudy: Old, New, and Evolving Strategies) (9), and CAC-
US (Coronary Bifurcation Application of the Crush
echnique Using Sirolimus-Eluting Stents) (10) trials, by
roviding a glimpse into “real-world practice.”
Randomized trials comparing strategies for the treatment
f bifurcation disease are particularly challenging. Angio-
raphic tools for assessing bifurcation lesions are still evolv-
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196ng. Though the Medina classification has provided a
traightforward way to classify lesions, the reliability and
rognostic capabilities of this tool have not been fully
alidated (11,12). Similarly, quantitative edge detection
lgorithms have recently been developed and are being
ssessed by leading core angiographic laboratories (12). The
elatively small myocardial territory perfused by side
ranches make clinical events subtle and difficult to use as
tudy end points. Finally, investigators are likely to be
eluctant to enroll patients with a lesion when, in their
ersonal judgments, there is not equipoise between the 2
est strategies, such as a Medina 1.1.1 lesion with a large
ide branch that is likely to require side branch stenting. The
ecently presented BBC ONE study (9) provides a good
llustration. This large multicenter, randomized trial ran-
omized 500 patients to a simple (stepwise T-provisional
tenting) or a complex (crush or culotte) treatment strategy.
lthough the recruitment criteria were broad, both the long
ecruitment period (21 centers for 3 years) and the unex-
ectedly low use of side branch stent (2.8%) in patients
ssigned to the simple treatment strategy imply that these
ases were highly selected. The concern is that patients with
esions at highest risk may not have been included (8).
For all these reasons, large series with angiographic
ollow-up as presented by the Catania group (6) contribute
o our knowledge as we try to select the best therapy for our
atients. Furthermore, these data highlight an important
ole for dedicated 2 stent strategies when treating high risk
ifurcation lesions.
eprint requests and correspondence: Dr. Aaron V. Kaplan,
rofessor of Medicine, Dartmouth Medical School, Director of
esearch, Cardiac Catheterization Laboratories, One Medical
enter Drive, Lebanon, New Hampshire 03756-0001. E-mail:aron.v.kaplan@hitchcock.org.
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